Navigation Links
PRI Condemns PEPFAR Amendments
Date:2/6/2008

FRONT ROYAL, Va., Feb. 6 /PRNewswire-USNewswire/ --- Population Research Institute has joined other pro-life groups in condemning amendments to the President's Emergency Plan for AIDS Relief (PEPFAR).

PEPFAR is up for reauthorization on Thursday, February 14, 2008, in the House Foreign Affairs Committee. According to PRI's president Steven Mosher, the preliminary drafts have been compromised by amendments that put the money directly in the hands of known population controllers.

"It would be better if President Bush had never proposed PEPFAR, than to have 50 billion dollars hijacked by abortion-promoting, chastity-mocking, anti-people groups like IPPF, UNFPA, and the Chinese government," said Mosher. "If the amendments promoted by the Democrat majority are passed, a veto will be the President's only option."

These amendments include "family planning" language that does not exclude abortion, lifting important abortion restrictions imposed by the Mexico City Policy, a removal of the anti-prostitution pledge, and a full integration of family planning services with HIV aid services.

PRI urges pro-lifers everywhere to contact the members of the House Foreign Affairs Committee and encourage them to vote against this bill. Information about this committee can be found at http://www.foreignaffairs.house.gov.

The Population Research Institute (PRI) was founded in 1989 by Fr. Paul Marx, OSB, PhD and is dedicated to: (1) ending human rights abuses committed in the name of "family planning," (2) opposing outdated social and economic paradigms premised on the myth of overpopulation, (3) informing the public about the social and economic benefits of moderate population growth, and (4) promoting pro-natal and pro-family attitudes and policies worldwide.


'/>"/>
SOURCE Population Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Catholic Health Association Condemns Denial of Health Insurance for Children
2. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
3. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: